Product Description
L218CAR19 is a kind of chimeric antigen receptor T-cell immunotherapy targeting CD19 on B cells. (Sourced from: https://clinicaltrials.gov/study/NCT06478381)
Mechanisms of Action: CAR-T,CD19
Novel Mechanism: No
Modality: Cell Therapy
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Henan Cancer Hospital
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Lymphoma, B-Cell
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| HNSZLYYML09 | P1 |
Recruiting |
Lymphoma, B-Cell |
2025-12-31 |